Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study |
| |
| Affiliation: | 1. Northwestern University Feinberg Medical School, Chicago, Illinois;2. Celgene Corporation, Summit, New Jersey;3. University of Texas Health Science Center–San Antonio, San Antonio, Texas;4. Hospital Universitario La Paz, Madrid, Spain;5. Pediatric Department, University of Alberta, Edmonton, Canada |
| |
| Abstract: | |
| |
| Keywords: | adolescent apremilast children pediatric pharmacokinetics plaque psoriasis safety AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0050" }," $$" :[{" #name" :" text" ," _" :" adverse event area under the concentration-time curve from time 0 to 12 hours after the dose area under the concentration-time curve from time 0 to the last quantifiable concentration BMI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0080" }," $$" :[{" #name" :" text" ," _" :" body mass index BSA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0090" }," $$" :[{" #name" :" text" ," _" :" body surface area CL/F" },{" #name" :" keyword" ," $" :{" id" :" kwrd0100" }," $$" :[{" #name" :" text" ," _" :" apparent total plasma clearance maximal observed plasma concentration PASI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0120" }," $$" :[{" #name" :" text" ," _" :" Psoriasis Area and Severity Index PK" },{" #name" :" keyword" ," $" :{" id" :" kwrd0130" }," $$" :[{" #name" :" text" ," _" :" pharmacokinetic TEAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0140" }," $$" :[{" #name" :" text" ," _" :" treatment-emergent adverse event |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
